[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 878,641
  • Shares Outstanding, K 39,348
  • Annual Sales, $ 726,410 K
  • Annual Income, $ 7,030 K
  • EBIT $ 81 M
  • EBITDA $ 170 M
  • 60-Month Beta 0.29
  • Price/Sales 1.23
  • Price/Cash Flow 5.79
  • Price/Book 1.34

Options Overview Details

View History
  • Implied Volatility 48.83% (+0.17%)
  • Historical Volatility 27.65%
  • IV Percentile 10%
  • IV Rank 10.90%
  • IV High 128.93% on 03/16/26
  • IV Low 39.03% on 08/20/25
  • Expected Move (DTE 25) 1.06 (4.76%)
  • Put/Call Vol Ratio 0.36
  • Today's Volume 19
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 1,018
  • Open Int (30-Day) 1,020
  • Expected Range 21.27 to 23.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.27
  • Number of Estimates 1
  • High Estimate $0.27
  • Low Estimate $0.27
  • Prior Year $0.47
  • Growth Rate Est. (year over year) -42.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.92 +1.87%
on 05/20/26
25.17 -11.28%
on 05/27/26
-0.11 (-0.49%)
since 05/18/26
3-Month
21.84 +2.24%
on 03/20/26
27.13 -17.69%
on 05/01/26
+0.31 (+1.41%)
since 03/18/26
52-Week
18.80 +18.78%
on 01/20/26
27.64 -19.21%
on 09/03/25
-1.82 (-7.54%)
since 06/18/25

Most Recent Stories

More News
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting

BRISBANE, Calif. , June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain...

PCRX : 22.33 (-1.37%)
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting

Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward Momentum

PCRX : 22.33 (-1.37%)
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

ISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change"

PCRX : 22.33 (-1.37%)
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees

BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid...

PCRX : 22.33 (-1.37%)
DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION

PACIRA'S STOCK PRICE IS DOWN FOR EVERY RECENT PERIOD: 10 YEAR, 5 YEAR, 3 YEAR, 2 YEAR, ONE YEAR, AND YEAR-TO-DATE

PCRX : 22.33 (-1.37%)
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees

Clarifies DOMA’s Inaccuracies and the Reality of Pacira’ Efforts to Strengthen its Market Position Urges Stockholders to Vote “ FOR ” the Election of Pacira’s Highly Qualified Nominees...

PCRX : 22.33 (-1.37%)
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty

Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL use BRISBANE, Calif., May 27, 2026 (GLOBE...

PCRX : 22.33 (-1.37%)
Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy

Urges Stockholders to Vote “ FOR ” the Election of Pacira’s Highly Qualified Nominees on the  BLUE  Proxy Card Today BRISBANE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences,...

PCRX : 22.33 (-1.37%)
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC

FRANK LEE AND THE BOARD HAVE OVERSEEN GROSS AND PERSISTENT UNDERPERFORMANCE FOR YEARS. WHY WOULD SHAREHOLDERS VOTE TO CONTINUE THIS UNRELENTING LACK OF TOTAL RETURN TO SHAREHOLDERS ("TRS"), WHILE ALLOWING...

PCRX : 22.33 (-1.37%)
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences

Independent Directors, Christopher Dennis, MD, MBA, FAPA and Oliver Benton "Ben" Curtis III Outline How Their Skills and Experience Will Drive Positive Change

PCRX : 22.33 (-1.37%)

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 23.55
2nd Resistance Point 23.25
1st Resistance Point 22.79
Last Price 22.33
1st Support Level 22.03
2nd Support Level 21.73
3rd Support Level 21.27

See More

52-Week High 27.64
Fibonacci 61.8% 24.26
Fibonacci 50% 23.22
Last Price 22.33
Fibonacci 38.2% 22.18
52-Week Low 18.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.